The present application discloses new PEG-interferon lambda 1 conjugates (PEG-????1), processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to ????1 and are effective in the treatment of hepatitis B and hepatitis C.